Truist Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $8
Perspective Therapeutics Analysts Slash Their Forecasts After Q3 Results
Wedbush Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $7
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $8
Perspective Therapeutics: Q3 Earnings Snapshot
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026
Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
Perspective Therapeutics (CATX) Stock Sees Fair Value Moves Lower As Analysts Weigh Lead 212 Risks
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
Perspective Therapeutics Reveals Acceptance Of [212Pb]VMT01 Data For Presentation At SITC 2026
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.